Phthalazine Compounds Modulating Kinase Activity for Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to addressing TNF-α, IL-1β, and IL-6 mediated diseases, such as inflammation and pain, are limited in efficacy and specificity, particularly in modulating kinase activity to treat conditions like rheumatoid arthritis and diabetes.
Innovation Solution
Development of a new class of compounds defined by general Formula I and II, which modulate kinase activity, including p38 kinase enzyme, for the prophylaxis and treatment of TNF-α, IL-1β, IL-6, and IL-8 mediated diseases, formulated into pharmaceutical compositions for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current approaches to addressing TNF-α, IL-1β, and IL-6 mediated diseases are used, then treatment is provided, but efficacy and specificity are limited
Solution Approach 1:
The patent employs parameter changes by developing compounds with specific molecular structures (Formula I and II) that target kinase enzymes with altered specificity. The compounds feature modified heteroaryl groups, substituent patterns, and stereochemical configurations that enhance binding affinity and selectivity for specific kinases involved in cytokine production, thereby improving both efficacy and specificity simultaneously
Solution Approach 2:
The invention uses composite molecular structures combining multiple pharmacophoric elements: core heteroaryl rings, linking groups, and diverse substituents (R1-R6). This composite approach creates molecules with optimized properties for dual targeting of kinase enzymes and cytokine pathways, resolving the contradiction between efficacy and specificity
2Adaptability or versatility
If kinase activity is modulated to treat inflammatory diseases, then targeted therapy is achieved, but selectivity among different kinase pathways is reduced
Solution Approach 1:
The patent applies local quality by designing compounds where specific regions of the molecule (such as R3, R4, and R5 substituents) are optimized for binding to particular amino acid residues in the kinase active site. This localized optimization allows the compound to distinguish between similar kinase pathways, maintaining targeted therapy while improving selectivity through region-specific molecular interactions
Data Source
AI summary
The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula Iwherein B, R1, R2, R3, R4 and R5 are d.efined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.